| Bioactivity | TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. | ||||||||||||
| Name | TAK-020 | ||||||||||||
| CAS | 1627603-21-7 | ||||||||||||
| Formula | C18H17N5O3 | ||||||||||||
| Molar Mass | 351.36 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):1289 |